Награды Comparably

Blueprint Medicines Corporation Заявленная компания

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to?rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. читать еще

Эта компания принимает отзывы от проверенных сотрудников СОТРУДНИКИ УЧАСТНИКИ: 81

ИТОГО РЕЙТИНГИ: 2321

СЕО: Kate Haviland

Kate Haviland Blueprint Medicines Corporation CEO Rating

Blueprint Medicines Corporation's CEO, Kate Haviland, has 80 employee ratings and a score of 89/100, placing them in the Top 5% of similar size companies on Comparably with 501-1000 сотрудников and Top 5% of other companies in Boston. When breaking the CEO score down by factors such as department, gender, and ethnicity, we see that males at Blueprint Medicines Corporation rate Kate Haviland higher than females, giving the CEO a score of 89/100.

Last updated months ago.

Where This Score Ranks Blueprint Medicines Corporation's CEO Rating

TOP
5%
In the Top 5% of 1832 Similar Sized Companies on Comparably
TOP
5%
In the Top 5% of 270 Nearby Companies in Boston
2nd
2nd place versus 3 competitors rated on Comparably

A+89 / 100

Jan

Blueprint Medicines Corporation CEO Kate Haviland Bio

Ms. Haviland joined Blueprint Medicines in January 2016 as Chief Business Officer and has served as Chief Operating Officer since January 2019. Over this time, she served as the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings. In addition, she directly supported the company's evolution into a fully integrated business by developing and providing ongoing management of critical functions, including portfolio strategy and program management, corporate development, commercial strategy, international, technical operations, corporate affairs, and information systems. Prior to joining Blueprint Medicines, Ms. Haviland held leadership roles focused on building emerging, high-growth companies and advancing the development of innovative therapies in oncology and rare diseases as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Head of Commercial Development at Sarepta Therapeutics, Executive Director of Commercial Development at PTC Therapeutics, and roles in both corporate development and project management at Genzyme. She holds a B.A. from Wesleyan University with a double major in Biochemistry/Molecular Biology and Economics and an M.B.A. from Harvard Business School. Ms. Haviland has served as an independent director on the board of Fulcrum Therapeutics since June 2018 and is a member of the audit and compensation committees.

Who Ranks Blueprint Medicines Corporation's CEO Rating the Highest?

Ethnicity - Asian or Pacific Islander 97/100

Experience - Entry Level 97/100

Department - COO 96/100

Who Ranks Blueprint Medicines Corporation's CEO Rating the Lowest?

Department - Sales 80/100

Department - Development 84/100

Ethnicity - Caucasian 87/100

Blueprint Medicines Corporation CEO Kate Haviland At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Blueprint Medicines Corporation.

Based on 80 ratings, Kate Haviland ranks right below Seattle Genetics' CEO, Clay Siegall.

Blueprint Medicines Corporation's CEO is highly regarded by Asian or Pacific Islander employees, employees with Entry Level experience, and the COO department. However, the Sales department, the Development department, and Caucasian employees have a less favorable view of the CEO and believe there is room for improvement. Overall, the CEO score has remained stable over the last 90 days.